Comparative effects of second-line therapy with obeticholic acid or fibrates in primary biliary cholangitis patients

Reig, A.; Álvarez-Navascués, Carmen; Gómez, Mercedes Vergara; Domińguez, Elena Gómez; Moya, Adolfo Gallego; Pérez-Medrano, Indhira; Fábrega, Emilio; Guerra, Manuel Hernández; Haym, Marina Berenguer; Estévez, Pamela; Almeida, Ana Arencibia; Morillas, Rosa; Horta, Diana; Albillos, Agustı́n; Casado, Marta; Cruz, Gemma De la; Bonilla, Eva Fernandez; Molina, Esther; Hijona, Lander; Diago, M.; Rodríguez, Conrado M Fernández; González-Santiago, Jesús M.; Sala, María; Gómez‐Camarero, Judith; Gómez, Manuel Romero; Suárez, Francisco; Blasco, Vićtor Manuel Vargas; Aracil, Carlos Ferre; Andrade, Raúl J.; Chahri, Nadia; Parés, Albert

doi:10.1016/s0168-8278(20)31404-5

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To compare the efficacy of OCA and fibrates as second-line therapies, a multicentric retrospective study including PBC patients from 30 centers has been undertaken in Spain [ 42 ]. A total of 86 patients receiving OCA (5 mg), 250 patients receiving fibrates (81% BEZA 400 mg, 19% FENO 200 mg), and 15 receiving OCA plus fibrates were enrolled.…”

Section: Other Therapeutic Agents For Pbcmentioning

confidence: 99%

Update on the Pharmacological Treatment of Primary Biliary Cholangitis

2022

View full text Add to dashboard Cite

Ursodeoxycholic acid (UDCA) is the first-line therapy used for the treatment of PBC. In recent years, new pharmacological agents have been proposed for PBC therapy to cure UDCA-non-responders. Obeticholic acid (OCA) is registered in many countries for PBC, and fibrates also seem to be effective in ameliorating biochemistry alteration and symptoms typical of PBC. Moreover, a variety of new agents, acting with different mechanisms of action, are under clinical evaluation for PBC treatment, including PPAR agonists, anti-NOX agents, immunomodulators, and mesenchymal stem cell transplantation. Since an insufficient amount of data is currently available about the effect of these novel approaches on robust clinical endpoints, such as transplant-free survival, their clinical approval needs to be supported by the consistent improvement of these parameters. The intensive research in this field will hopefully lead to a novel treatment landscape for PBC in the near future, with innovative therapies based on the combination of multiple agents acting on different pathogenetic mechanisms.

show abstract

Section: Other Therapeutic Agents For Pbcmentioning

confidence: 99%

Update on the Pharmacological Treatment of Primary Biliary Cholangitis

2022

View full text Add to dashboard Cite

show abstract

“…A comparative effect of second line therapy with OCA or fibrates has been evaluated in a multicentre retrospective study including 277 PBC patients from 30 centres in Spain. 29 Sixty-five patients received OCA (5 mg) and 201 fibrates (85% bezafibrate 400 mg, 16% fenofibrate 200 mg) and 11 OCA and fibrates. Fibrates were associated with higher decrease in ALP, while OCA with higher transaminases improvement.…”

Section: Introductionmentioning

confidence: 99%

<p>Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis</p>

Floreani

2020

JEP

View full text Add to dashboard Cite

The standard therapy for primary biliary cholangitis (PBC) is ursodeoxycholic acid (UDCA) which has shown to improve hepatic biochemistry, delay histological progression and improve transplant-free survival. Approximately 30–40% of patients do not respond or are intolerant to UDCA. Obeticholic acid, a farnesoid X receptor (FXR) agonist is the only agent approved by the Food and Drug Administration for patients who do not respond to UDCA. Recently, combination therapy with UDCA and bezafibrate has been shown to improve biochemistry and both GLOBE and UK-PBC score in patients with an inadequate response to UDCA. More recently, new pharmacological agents have been included in Phase 2 and Phase 3 trials: PPAR agonists, non-bile acid FXR agonists, anti-NOX agents, immunomodulators and mesenchymal stem cells transplantation. This review gives an overview on the current experimental pharmacological agents employed in the treatment of PBC.

show abstract

Comparative effects of second-line therapy with obeticholic acid or fibrates in primary biliary cholangitis patients

Cited by 2 publications

References 0 publications

Update on the Pharmacological Treatment of Primary Biliary Cholangitis

Update on the Pharmacological Treatment of Primary Biliary Cholangitis

<p>Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis</p>

Contact Info

Product

Resources

About